Journals / Ege Klinikleri Tıp Dergisi / 2021 / Cilt: 59 - Sayı: 3

Research of Atherosclerotic Biomarkers in Contrast Layering Cases

Kontrast Layering Olgularında Aterosklerotik Biyobelirteçlerin Araştırılması

Pages
1–8
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Our results show that there is a relationship between CL phenomenon and atherosclerosis on the basis of all biomarkers except IL-6.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Many biomarkers such as High-sensitive C-Reactive protein (hsCRP); Interleukin 1 beta (IL-1β); Interleukin 6 (IL-6); Soluble CD40 Ligand (sCD40L); and Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) are considered to be involved in early stages of atherosclerosis.
📊
Key Findings & Data:Methods: The levels of hsCRP, IL-1β, IL-6, sCD40L and Lp-PLA2 were measured using the method of the quantitative sandwich enzyme immunoassay according to manufacturer’s instructions.
💡
Conclusion & Impact:Conclusions: Our results show that there is a relationship between CL phenomenon and atherosclerosis on the basis of all biomarkers except IL-6.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Many biomarkers such as High-sensitive C-Reactive protein (hsCRP); Interleukin 1 beta (IL-1β); Interleukin 6 (IL-6); Soluble CD40 Ligand (sCD40L); and Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) are considered to be involved in early stages of atherosclerosis. Contrast layering (CL) phenomenon is suggested to detect early atherosclerosis. The first aim of this study was to investigate the relationship between CL and some atherosclerotic biomarkers seen in atherosclerosis process. Secondly, we aimed to reveal the relationship between the intensity and severity of the CL phenomenon and the biomarker levels. Methods: The levels of hsCRP, IL-1β, IL-6, sCD40L and Lp-PLA2 were measured using the method of the quantitative sandwich enzyme immunoassay according to manufacturer’s instructions. Contrast layering is defined as the relatively late clearance of the injected contrast medium from normal coronary artery segments with normal TIMI flow, without any atherosclerotic lesion or dissection during coronary angiography. This study included 1723 patients who underwent elective coronary angiography in our clinic. In 50 of these patients, a contrast layer was detected and included in the study group. 37 patients with normal coronary angiography were included in the control group. Results: Atherosclerotic biomarker levels were found to be higher than all biomarker levels in the CL group compared to the control group. The difference in all biomarker levels between CL group and control group except IL-6 was statistically significant. Contrast layering was detected in one vessel in 20 patients (40%), in two vessels in 21 patients (42%) and in three vessels in 9 patients. The mean CL length in the CL group was 79,1 ± 40,8 (mm) (range 9,7-200 mm), the average number of CL frames was 68,2 ± 35,5 (range 10-153 frames). No statistically significant difference was observed between biomarkers and the number of frames and the length of CL. Conclusions: Our results show that there is a relationship between CL phenomenon and atherosclerosis on the basis of all biomarkers except IL-6. However, we could not find a relationship between the biomarker levels and the number of vessels, the length of the CL and CL frame number.

Özet

Amaç: Yüksek duyarlı C-reaktif protein (hsCRP); interlökin 1 beta (IL1β); interlökin 6 (IL-6); çözünürCD40 Ligand (sCD40L) ve lipoproteinAssociated fosfolipaz A2 (Lp-PLA2) gibi biyobelirteçlerin aterosklerozun erken evrelerinde yeraldığı bilinmektedir. Kontrast Layering (CL) fenomeni ile ateroskleroz varlığı arasında bir ilişki olduğu düşünülmektedir. Biz bu çalışmada öncelikle, ateroskleroz sürecinde rolü olan biyobelirteçler ile CL arasındaki ilişkiyi göstermeyi hedefledik. İkinci olarak ise CL fenomeninin şiddeti ile biyobelirteç seviyeleri arasındaki ilişkiyi ortaya koymayı amaçladık. Yöntemler: hsCRP, IL-1β, IL-6, çözün sCD40L ve Lp-PLA2 seviyeleri enzim immünoassay yöntemi kullanılarak ölçüldü. CL fenomeni coroner anjiyografi sırasında herhangi bir aterosklerotik lezyon veya diseksiyon olmaksızın, normal TIMI akışı olan normal koroner arter segmentlerinde enjekte edilen kontrast maddenin nispeten geç temizlenmesi olarak tanımlanır. Bu çalışmaya kliniğimizde elektif koroner anjiyografi yapılan 1723 hasta dahil edildi. Bu hastaların en az bir koroner arterde kontrast tabakalanma tespit edilen hastaları çalışma grubuna dahil edildi. Normal koroner anjiyografili 37 hasta ise kontrol grubuna dahil edildi. Bulgular: Çalışmada araştırılan aterosklerotik biyobelirteç düzeylerinin tamamı CL grubunda control grubuna oranla daha yüksek ölçüldü. IL-6 dışındaki tüm biyobelirteç seviyelerindeki fark istatistiksel olarak anlamlıydı. CL, 20 hastada (%40) bir damarda, 21 hastada (%42) iki damarda ve 9 hastada üç damarda tespit edildi. CL grubunda ortalama CL uzunluğu 79,1 ± 40,8 (mm) (aralık 9,7-200 mm), ortalama frame sayısı 68,2 ± 35,5 (aralık 10-153 frame) idi. Biyobelirteçler ile CL uzunluğu ve frame sayısı arasında istatistiksel olarak anlamlı bir fark gözlenmedi. Sonuç: Biz bu çalışmada aterosklerotik biyobelirteçler temelinde CL fenomeni ile ateroskleroz arasında bir ilişki olduğunu gösterdik. Bununla birlikte, biyobelirteç seviyeleri ile damar sayısı, CL uzunluğu ve Cl frame sayısı arasında bir ilişki bulamadık. Anahtar Kelimeler: Ateroskleroz; Biyobeli

🔖

Cite This Article

SAHİN, M. H., ERTUĞRUL, A. S., KARABULUT, D., PİRHAN, O., NEİJMANN, S. T., KOŞAR, M. F. (2022). Research of Atherosclerotic Biomarkers in Contrast Layering Cases. Ege Klinikleri Tıp Dergisi, Cilt: 59 - Sayı: 3, 1–8. https://ajindex.com/articles/495608

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998; 97(11):1095-1102
  2. Caglar IM, Demir B, Caglar FNT, et al. Contrast Layering: Late Clearance of Contrast Dye—A Novel Angiographic Phenomenon of Early Atherosclerosis. Angiology 2015; 66(2):136-142
  3. Du Clos TW. Function of C-reactive protein. Ann Med 2000; 32(4):274-278
  4. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47(3):403-411
  5. Masood A, Jafar SS, Akram Z. Serum high sensitivity C-reactive protein levels and the severity of coronary atherosclerosis assessed by angiographic gensini score. J Pak Med Assoc 2011; 61:325-327
  6. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. New England Journal of Medicine 1993; 328(2):106-113
  7. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. The American journal of pathology 1991; 138(4):951
  8. Calderon TM, Factor SM, Hatcher VB, Berliner J Berman JW. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9. Expression in vivo in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels. Lab Invest 1994; 70(6):836-849
  9. Libby P, Ordovas JM, Birinyi LK,Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest 1986; 78: 1432-1438
  10. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618-623
  11. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993; 14: 118-124
  12. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101(15):1767-1772
  13. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101(12):1372-1378
  14. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unst